1
|
Bachert C, Marple B, Schlosser RJ, Hopkins C, Schleimer RP, Lambrecht BN, Bröker BM, Laidlaw T, Song WJ. Adult chronic rhinosinusitis. Nat Rev Dis Primers 2020; 6:86. [PMID: 33122665 DOI: 10.1038/s41572-020-00218-1] [Citation(s) in RCA: 126] [Impact Index Per Article: 31.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/09/2020] [Indexed: 02/06/2023]
Abstract
Chronic rhinosinusitis (CRS) occurs in >10% of the adult population in Europe and the USA and can be differentiated into CRS without nasal polyps and CRS with nasal polyps (CRSwNP). Both phenotypes are characterized by a high disease burden and an overlapping spectrum of symptoms, with facial pain and loss of smell being the most differentiating. Great progress has been made in the understanding of CRS pathophysiology: from the epithelium and epithelial-mesenchymal transition to innate and adaptive immunity pathways and, finally, on the role of eosinophils and Staphylococcus aureus in the persistence of disease. Although clinical manifestations and diagnostic tools (including nasal endoscopy and imaging) have undergone major changes over the past few years, management (including pharmacotherapy, surgery and biologics) has experienced enormous progress based on the growing knowledge of key mediators in severe CRSwNP. The introduction of endotyping has led to a differentiation of 'tailored' surgical approaches, focusing on the mucosal concept in those with severe CRSwNP and on the identification of patients eligible for extended surgery and possibly biologics in the future.
Collapse
Affiliation(s)
- Claus Bachert
- Sun Yat-sen University, International Airway Research Center, First Affiliated Hospital, Guangzhou, China.
- Upper Airways Research Laboratory, Ghent University, Ghent, Belgium.
- Division of ENT diseases, CLINTEC, Karolinska Institute, University of Stockholm, Stockholm, Sweden.
| | - Bradley Marple
- University of Texas, Southwestern Medical Center, Department of Otolaryngology - Head and Neck Surgery, Dallas, TX, USA
| | - Rodney J Schlosser
- Medical University of South Carolina, Department of Otolaryngology - Head and Neck Surgery, Charleston, SC, USA
| | | | - Robert P Schleimer
- Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Bart N Lambrecht
- Laboratory of Immunoregulation, VIB-UGhent Center for Inflammation Research, Ghent, Belgium
- Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium
- Department of Pulmonary Medicine, ErasmusMC, Rotterdam, Netherlands
| | - Barbara M Bröker
- Department of Immunology, Institute of Immunology and Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany
| | - Tanya Laidlaw
- Department of Medicine, Harvard Medical School, the Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA
| | - Woo-Jung Song
- Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| |
Collapse
|
2
|
Studzinski GP, Shankavaram UT, Moore DC, Reddy PV. Association of c-myc protein with enzymes of DNA replication in high molecular weight fractions from mammalian cells. J Cell Physiol 1991; 147:412-9. [PMID: 1648564 DOI: 10.1002/jcp.1041470305] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Oncoprotein c-myc is expressed in proliferating but not quiescent mammalian cells, and its overexpression or inappropriate expression is associated with malignant transformation. However, in spite of an intense interest, the normal function of this protein has remained elusive. As a step towards the elucidation of the function of c-myc protein, we studied its distribution within several types of cells, including HL 60, K 562, COLO 320, and CHEF/18 cells. In all of the cells studied, c-myc protein was detected in high molecular weight protein fractions, in 350-600 Kd range, in gel-exclusion chromatography and sucrose gradient centrifugation. This distribution of c-myc protein coincided with the distribution of DNA polymerase alpha and several other enzymes necessary for DNA replication. The data suggest that c-myc product may be a component of the replitase complex of enzymes involved in nuclear DNA replication.
Collapse
Affiliation(s)
- G P Studzinski
- Department of Laboratory Medicine and Pathology, UMDNJ-New Jersey Medical School, Newark 07103
| | | | | | | |
Collapse
|
3
|
Kerkhoff E, Bister K, Klempnauer KH. Sequence-specific DNA binding by Myc proteins. Proc Natl Acad Sci U S A 1991; 88:4323-7. [PMID: 1827916 PMCID: PMC51651 DOI: 10.1073/pnas.88.10.4323] [Citation(s) in RCA: 95] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Myc proteins have a tripartite carboxyl-terminal domain containing specific amino acid sequence motifs: a basic motif, a helix-loop-helix motif, and a leucine heptad repeat. Similar sequence motifs have been identified in several eukaryotic transcription factors and were shown to facilitate protein-DNA and protein-protein interactions. By using recombinant v-Myc proteins obtained by bacterial expression of full-length or partially deleted avian v-myc alleles, the functional relevance of these sequence motifs for Myc protein oligomerization and for DNA binding was investigated. All recombinant v-Myc proteins that have retained the carboxyl-terminal domain dimerize and specifically bind to double-stranded DNA containing the palindromic core sequence CACGTG. This and a closely related DNA sequence element have been defined previously as part of the binding sites for human transcription factors USF and TFE3, which specifically bind to the adenovirus major late promoter or the muE3 motif within the immunoglobulin heavy-chain enhancer, respectively. It is shown that a 61-amino-acid peptide sequence containing only the bipartite basic motif/helix-loop-helix domain of Myc is necessary and sufficient for dimerization and sequence-specific DNA binding of v-Myc recombinant proteins.
Collapse
Affiliation(s)
- E Kerkhoff
- Institute of Biochemistry, Medical School, University of Cologne, Federal Republic of Germany
| | | | | |
Collapse
|
4
|
Affiliation(s)
- K Saksela
- Department of Virology, University of Helsinki, Finland
| |
Collapse
|
5
|
Abstract
In spite of the complexity of the network of regulatory factors which control the balance between the cell cycle and quiescence, a picture is emerging, if only in outline. Several dozens of protooncogenes participate in growth signal transduction and integration, and, when expressed inappropriately, generate growth signals that may override other cellular controls. Some of these controls are provided by the negatively regulating growth factors, and when these are lost (e.g. by chromosomal deletion), or inactivated (e.g. by binding to an inactive analogue or a DNA viral oncoprotein), cell cycle activity is favoured over quiescence. Embryonic tissues are rapidly growing, so their cells are actively cycling and expression of proto-oncogenes is usually observed (Schuuring et al., 1989). As embryonic and stem cells in adult tissues mature, expression of the active proto-oncogenes is generally lost, but other proto-oncogenes may now be expressed (e.g. Muller et al., 1982). These changes in proto-oncogene expression are not achieved by modulation of transcriptional rates alone; transcriptional attenuation, message processing and stability, and post-translational protein modifications are all known to be important for the regulation of proto-oncogene expression during the transition from growth to the differentiated state. When quiescent cells re-enter the cell cycle approximately 60 genes become up-regulated, including proto-oncogene c-fos, the jun family, and c-myc (Zipfel et al., 1989). Evidence is strong that fos and jun proteins are transcriptional regulators. Terminal differentiation, on the other hand, is sometimes accompanied by the up-regulation of the ras gene family, as well as of several other proto-oncogenes. Proto-oncogene function is essential to the cell cycle traverse, but the genes involved are different in various cell types, and the precise order of oncogene expression may not turn out to be important. This is because cell cycle traverse appears to be more dependent on a critical threshold of growth signals propagated by parallel pathways, rather than on a strict order of predetermined steps. The participation of proto-oncogenes in growth signal transduction offers opportunities for errors, and abnormal growth may result from aberrant oncogene products generating a persistent or excessive growth signal, which shifts the balance of input to the integrating genes from quiescence to an active cell cycle. Thus, cancer may result from an entirely normal processing of growth signals that are abnormal.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- G P Studzinski
- Department of Pathology, UMDNJ-New Jersey Medical School, Newark 07103-2757
| |
Collapse
|
6
|
Two N-myc polypeptides with distinct amino termini encoded by the second and third exons of the gene. Mol Cell Biol 1989. [PMID: 2657399 DOI: 10.1128/mcb.9.4.1545] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The N-myc and c-myc genes encode closely related nuclear phosphoproteins. We found that the N-myc protein from human tumor cell lines appears as four closely migrating polypeptide bands (p58 to p64) in sodium dodecyl sulfate-polyacrylamide gels. This and the recent finding that the c-myc protein is synthesized from two translational initiation sites located in the first and second exons of the gene (S. R. Hann, M. W. King, D. L. Bentley, C. W. Anderson, and R. N. Eisenman, Cell 52:185-195, 1988) prompted us to study the molecular basis of the N-myc protein heterogeneity. Dephosphorylation by alkaline phosphatase reduced the four polypeptide bands to a doublet with an electrophoretic mobility corresponding to the two faster-migrating N-myc polypeptides (p58 and p60). When expressed transiently in COS cells, an N-myc deletion construct lacking the first exon produced polypeptides similar to the wild-type N-myc protein, indicating that the first exon of the N-myc gene is noncoding. Furthermore, mutants deleted of up to two thirds of C-terminal coding domains still retained the capacity to produce a doublet of polypeptides, suggesting distinct amino termini for the two N-myc polypeptides. The amino-terminal primary structure of the N-myc protein was studied by site-specific point mutagenesis of the 5' end of the long open reading frame and by N-terminal radiosequencing of the two polypeptides. Our results show that the N-myc polypeptides are initiated from two alternative in-phase AUG codons located 24 base pairs apart at the 5' end of the second exon. Both of these polypeptides are phosphorylated and localized to the nucleus even when expressed separately. Interestingly, DNA rearrangements activating the c-myc gene are often found in the 1.7-kilobase-pair region between the two c-myc translational initiation sites and correlate with the loss of the longer c-myc polypeptide. Thus the close spacing of the two N-myc initiation codons could explain the relative resistance of the N-myc gene to similar modes of oncogenic activation.
Collapse
|
7
|
Mäkelä TP, Saksela K, Alitalo K. Two N-myc polypeptides with distinct amino termini encoded by the second and third exons of the gene. Mol Cell Biol 1989; 9:1545-52. [PMID: 2657399 PMCID: PMC362571 DOI: 10.1128/mcb.9.4.1545-1552.1989] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The N-myc and c-myc genes encode closely related nuclear phosphoproteins. We found that the N-myc protein from human tumor cell lines appears as four closely migrating polypeptide bands (p58 to p64) in sodium dodecyl sulfate-polyacrylamide gels. This and the recent finding that the c-myc protein is synthesized from two translational initiation sites located in the first and second exons of the gene (S. R. Hann, M. W. King, D. L. Bentley, C. W. Anderson, and R. N. Eisenman, Cell 52:185-195, 1988) prompted us to study the molecular basis of the N-myc protein heterogeneity. Dephosphorylation by alkaline phosphatase reduced the four polypeptide bands to a doublet with an electrophoretic mobility corresponding to the two faster-migrating N-myc polypeptides (p58 and p60). When expressed transiently in COS cells, an N-myc deletion construct lacking the first exon produced polypeptides similar to the wild-type N-myc protein, indicating that the first exon of the N-myc gene is noncoding. Furthermore, mutants deleted of up to two thirds of C-terminal coding domains still retained the capacity to produce a doublet of polypeptides, suggesting distinct amino termini for the two N-myc polypeptides. The amino-terminal primary structure of the N-myc protein was studied by site-specific point mutagenesis of the 5' end of the long open reading frame and by N-terminal radiosequencing of the two polypeptides. Our results show that the N-myc polypeptides are initiated from two alternative in-phase AUG codons located 24 base pairs apart at the 5' end of the second exon. Both of these polypeptides are phosphorylated and localized to the nucleus even when expressed separately. Interestingly, DNA rearrangements activating the c-myc gene are often found in the 1.7-kilobase-pair region between the two c-myc translational initiation sites and correlate with the loss of the longer c-myc polypeptide. Thus the close spacing of the two N-myc initiation codons could explain the relative resistance of the N-myc gene to similar modes of oncogenic activation.
Collapse
Affiliation(s)
- T P Mäkelä
- Department of Virology, University of Helsinki, Finland
| | | | | |
Collapse
|
8
|
Dang CV, McGuire M, Buckmire M, Lee WM. Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein. Nature 1989; 337:664-6. [PMID: 2645525 DOI: 10.1038/337664a0] [Citation(s) in RCA: 163] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
c-Myc plays a part in the regulation of important cellular processes such as growth, differentiation and neoplastic transformation. Although c-myc gene structure and expression are well characterized, the function and biochemical properties of the protein are less well understood. Human c-myc is a 439-amino acid phosphoprotein which binds DNA in vitro and belongs to a discrete subset of nuclear proteins. Using the human c-myc mutants generated by linker-insertion and deletion mutagenesis, we have defined regions of the protein that are important for its transforming activities and its nuclear localization. Here, we show that human c-myc exists as an oligomer in vitro and use mutant proteins to localize the oligomerization domain to a carboxyl-terminal peptide containing the 'leucine zipper' motif. The 'leucine zipper' describes a structure found in a number of DNA-binding proteins that contains leucines occurring at intervals of every seventh amino acid in a region predicted to be alpha-helical. The 'leucine zipper' might mediate dimerization by intermolecular interdigitation of the leucine side-chains. We show that a c-myc mutant, which is inactive but can oligomerize, dominantly inhibits the cotransforming activity with wild-type c-myc of rat embryo cells, whereas inactive mutants which cannot oligomerize properly because of deletions in the oligomerization domain are recessive.
Collapse
Affiliation(s)
- C V Dang
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
| | | | | | | |
Collapse
|
9
|
Abstract
Several members of the myc family of proto-oncogenes have been described, and some (c-, N-, and L-myc) have been characterized in considerable detail. They are united by a common gene structure and nucleotide homologies that were used to identify some of them initially. Their protein products also have scattered regions of amino acid identity or homology. Although the cellular activities of the various proteins are unknown, some members may play a role in regulating cell growth and differentiation. They share the ability to cooperate with an activated ras gene and cotransform embryonic rodent cells. In naturally occurring tumors, the members of the myc family of oncogenes appear to be activated by genetic changes (proviral insertion, chromosomal translocation, and gene amplification) that augment or otherwise disrupt normally regulated expression. The members of this family of genes differ markedly in their tissue specificity and developmental regulation of expression. This may account in part for the frequent appearance of activated c-myc genes in a wide variety of neoplasms and the limited appearance of activated N- and L-myc genes in tumors of embryonic or neural origin. The c-myc gene may be activated in tumors by a variety of mechanisms, whereas N- and L-myc appear to be activated only by gene amplification. Regulation of expression of the different myc genes also appears to occur by different mechanisms. Finally, the products of the different genes differ in may regions of the protein, and this divergence probably reflects their specific and individual functions.
Collapse
|
10
|
Potts WM, Vogt VM. A simple method for immunoaffinity purification of nondenatured avian sarcoma and leukemia virus gag-containing proteins. Virology 1987; 160:494-7. [PMID: 2821689 DOI: 10.1016/0042-6822(87)90024-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
We have developed a one-step purification procedure for proteins containing the N-terminal portion of the gag protein of avian sarcoma and leukemia viruses. In this procedure, a resin with a covalently attached monoclonal antibody to the gag protein p19 is used to bind gag-containing proteins from crude extracts. After washing of the resin, the bound proteins are eluted with 2 M MgCl2. For the transforming protein kinase encoded by Fujinami sarcoma virus p130gag-fps, this procedure gave an enrichment of several thousand-fold, a yield of over 10%, a final purity of over 20%, and no significant loss of protein kinase activity. Similar purifications were obtained with three other gag-containing proteins. The immunoaffinity purification described may be of general utility as a first step in purification of the several other avian retroviral transforming proteins that are synthesized from fusions of an oncogene with the viral gag gene.
Collapse
Affiliation(s)
- W M Potts
- Section of Biochemistry, Molecular and Cell Biology, Cornell University, Ithaca, New York 14853
| | | |
Collapse
|
11
|
Bader JP, Hausman FA, Ray DA. Intranuclear degradation of the transformation-inducing protein encoded by avian MC29 virus. J Biol Chem 1986. [DOI: 10.1016/s0021-9258(19)83912-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|